When prevention fails: Obesity treatment strategies

American Journal of Medicine

Volumn 122, Issue 4 SUPPL. 1, 2009, Pages

  Aronne, Louis J ^a   Wadden, Thomas ^b   Isoldi, Kathy Keenan ^a   Woodworth, Kristina A ^c  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c SciMantis Communications Inc   (United States)

Author keywords

Diet and lifestyle intervention; Exercise; Obesity treatment; Pharmacotherapy; Weight loss

Indexed keywords

ANOREXIGENIC AGENT;

DRUG EFFECT; EXERCISE; HUMAN; OBESITY; REVIEW; RISK REDUCTION; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; EXERCISE; HUMANS; OBESITY; RISK REDUCTION BEHAVIOR; WEIGHT LOSS;

EID: 66149100931     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.01.005     Document Type: Article

References (50)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
2. National Heart, Lung, and Blood Institute (NHLBI). The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health, Dept of Health and Human Services, October 2000. NIH Publication No. 00-4084.
3. Knowler WC, Barrett-Connor E, Fowler SE, et al, for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. (Pubitemid 34437694)
4. Tuomilehto J, Lindström J, Eriksson JG, et al, for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350. (Pubitemid 32378388)
5. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med. 2001;161:218-227. (Pubitemid 32102389)
6. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111-2120. (Pubitemid 41653103)
7. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532-546.
8. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM. 2007; 100:395-404. (Pubitemid 47062891)
9. Ness-Abramof R, Apovian CM. Drug-induced weight gain. Timely Top Med Cardiovasc Dis. 2005;9:E31.
10. Waitman JA, Aronne LJ. Pharmacological treatment. In: Foster G, Nonas C, eds. Managing Obesity: A Clinical Guide. Chicago: American Dietetic Association; 2004:151-173.
11. National Heart, Lung, and Blood Institute (NHLBI). The Evidence Report: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health, Dept of Health and Human Services, September 1998. NIH Publication No. 98-4083.
12. Scheen AJ, Van Gaal LF, Brohet C, de Backer G, Vissers E, Vandenhoven G. Belgian Evaluation of Screening and Treatment of high risk patients based on waist and age (BEST): focus on diabetes mellitus and metabolic syndrome. Presented at the 65th Annual Scientific Sessions of the American Diabetes Association; June 12, 2005; San Diego, CA.
13. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
14. International Diabetes Federation. The IDF Consensus worldwide definition of the metabolic syndrome. [IDF Website.] Brussels, Belgium: International Diabetes Federation, April 14, 2005. Available at: http://www.idf.org/webdata/ docs/Metabolic-syndrome-definition.pdf. Accessed April 16, 2007.
15. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
16. Foster G. The behavioral approach to treating obesity. Am Heart J. 2006;151:625-627. (Pubitemid 43290252)
17. Nordmann AJ, Nordmann A, Briel M, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006; 166:285-293. (Pubitemid 43244316)
18. Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. JAMA. 2007;297:2092-2102. (Pubitemid 46798167)
19. Gilden Tsai A, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver Spring). 2006;14:1283-1293. (Pubitemid 46219653)
20. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106:179-184. (Pubitemid 29115958)
21. Mathus-Vliegen EM. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-lowcalorie diet: a double-blind, placebo-controlled, parallel group study. Eur J Clin Nutr. 2005;59(suppl 1):S31-S38.
22. Ditschuneit HH, Flechtner-Mors M, Johnson TD, Adler G. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. Am J Clin Nutr. 1999;69:198-204. (Pubitemid 29065539)
23. Flechtner-Mors M, Ditschuneit HH, Johnson TD, Suchard MA, Adler G. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res. 2000;8:399-402.
24. US Department of Health and Human Services (HHS), US Department of Agriculture (USDA). Dietary Guidelines for Americans. [HHS Website.] Updated October 16, 2006. Washington, DC: Office of Disease Prevention and Health Promotion, US Dept of Health and Human Services, 2005. Available at: www.healthierus.gov/dietaryguidelines. Assessed June 21, 2007.
25. Lee CD, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr. 1999;69:373-380. (Pubitemid 29104555)
26. Stevens J, Cai J, Evenson KR, Thomas R. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the Lipid Research Clinics Study. Am J Epidemiol. 2002;156:832-841. (Pubitemid 35215764)
27. Redman LM, Heilbronn LK, Martin CK, Alfonso A, Smith SR, Ravussin E. Effect of calorie restriction with or without exercise on body composition and fat distribution. J Clin Endocrinol Metab. 2007;92: 865-872. (Pubitemid 46465656)
28. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005; 142:611-619. (Pubitemid 40529957)
29. Wadden TA, Crerand CE, Brock J. Behavioral treatment of obesity. Psychiatr Clin North Am. 2005;28:151-170. (Pubitemid 40279030)
30. Korner J, Aronne LJ. Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocrinol Metab. 2004;89:2616-2621. (Pubitemid 38766340)
31. Lowe MR. Self-regulation of energy intake in the prevention and treatment of obesity: is it feasible? Obes Res. 2003;11(suppl):44S-59S. (Pubitemid 41127405)
32. Ryan DH, Espeland MA, Foster GD, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003;24:610-628.
33. Jones LR, Wilson CI, Wadden TA. Lifestyle modification in the treatment of obesity: an educational challenge and opportunity. Clin Pharmacol Ther. 2007;81:776-779. (Pubitemid 46625116)
34. Lyznicki JM, Young DC, Riggs JA, Davis RM. Obesity: assessment and management in primary care. Am Fam Physician. 2001;63:2185-2196. (Pubitemid 32539022)
35. Gadde KM, Xiong GL. Bupropion for weight reduction. Expert Rev Neurother. 2007;7:17-24. (Pubitemid 46105291)
36. Stenlof K, Rossner S, Vercruysse F, Kumar A, Fitchet M, Sjostrom L. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab. 2007;9:360-368. (Pubitemid 46502056)
37. Riddle MC, Henry RR, Poon TH, et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev. 2006;22:483-491. (Pubitemid 44774053)
38. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebocontrolled trials. Clin Ther. 2007;29:139-153. (Pubitemid 46414034)
39. Scholze J, Grimm E, Herrmann D, Unger T, Kintscher U. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity- Sibutramine (HOS) study. Circulation. 2007;115:1991-1998. (Pubitemid 46625949)
40. Kyrou I, Valsamakis G, Tsigos C. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Ann N Y Acad Sci. 2006;1083:270-305. (Pubitemid 44955478)
41. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002;136:550-557. (Pubitemid 34717699)
42. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol. 2001;134:1151-1154. (Pubitemid 33097243)
43. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004;28:640-648. (Pubitemid 38491158)
44. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112:423-431. (Pubitemid 38063771)
45. Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr. 2004;92:757-761. (Pubitemid 39562153)
46. Pi-Sunyer FX, Aronne LJ, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients, RIO-North America: a randomized controlled trial. JAMA. 2006;295:761-775. (Pubitemid 43244304)
47. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389-1397. (Pubitemid 40523733)
48. Després JP, Golay A, Sjöstrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121-2134. (Pubitemid 41653104)
49. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660-1672. (Pubitemid 46048528)
50. Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation. 2006; 114:974-984. (Pubitemid 44337141)